HArmonyCa Lidocaine Injectable Gel

DEVICE2 trials

Sponsors

Allergan, AbbVie

Conditions

Mid Face Volume Deficit

Phase 3

A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

CompletedNCT05452070

AllerganMid Face Volume Deficit

Start: 2022-09-02End: 2025-05-08Updated: 2026-06-01

A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants

Active, not recruitingNCT07032597

AbbVieMid Face Volume Deficit

Start: 2025-05-26End: 2026-10-31Updated: 2025-08-14